Nuvectis Pharma reported a net loss of $30.1 million for the third quarter ended September 30, 2026, driven by a $20.0 million upfront license payment and milestone expenses associated with in-licensing NXP100 (ciprocopan) and NXP200 from Haisco Pharmaceutical Group. The company raised approximately $154.5 million through a follow-on public offering and ATM sales, bringing its cash position to $140.7 million as of September 30, 2026. This funding extends the company's operational runway into the second half of 2029. Nuvectis is a clinical-stage biopharmaceutical company focused on developing innovative therapies for complement-related conditions and oncology.
